Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Ischemic Stroke l: Introduction01:15

Ischemic Stroke l: Introduction

Ischemic stroke is an acute cerebrovascular condition in which blood flow to a brain region is suddenly interrupted, leading to tissue infarction. Neurons depend on continuous oxygen and glucose supply, so even brief reductions in perfusion cause energy failure, ionic imbalance, and irreversible injury. Ischemic strokes are classified into thrombotic and embolic types based on their underlying mechanisms.Thrombotic MechanismsThrombotic stroke develops when a clot forms within a cerebral artery.
Ischemic Stroke ll: Pathophysiology01:15

Ischemic Stroke ll: Pathophysiology

An ischemic stroke occurs when a cerebral blood vessel becomes obstructed, most often by a thrombus or embolus, interrupting the delivery of oxygen and glucose to brain tissue. Because neurons rely on continuous aerobic metabolism, energy failure begins within minutes of reduced perfusion. The region receiving the least blood flow becomes the infarct core, an area of irreversible cellular death. Surrounding this core lies the penumbra, a zone of hypoperfused but still viable tissue that is...
Hemorrhagic Stroke l: Introduction01:17

Hemorrhagic Stroke l: Introduction

A hemorrhagic stroke is an acute neurological event that occurs when a weakened cerebral blood vessel ruptures, allowing blood to accumulate within or around the brain. The sudden release of blood forms a focal hematoma that increases intracranial pressure, displaces neural tissue, and can obstruct cerebrospinal fluid pathways. These effects may be compounded by intraventricular extension of the hemorrhage, cerebral edema, or compression of adjacent structures, all of which contribute to...
Hemorrhagic Stroke ll: Pathophysiology01:29

Hemorrhagic Stroke ll: Pathophysiology

A hemorrhagic stroke develops when a cerebral blood vessel ruptures, allowing blood to escape into the surrounding brain tissue, as in intracerebral hemorrhage (ICH), or into the subarachnoid space, as in subarachnoid hemorrhage (SAH). Because the skull is a rigid compartment, the sudden presence of extravascular blood rapidly increases intracranial pressure and compresses adjacent neural structures, leading to immediate tissue injury and impaired cerebral perfusion.Mass Effect and Primary...
Transient Ischemic Attack l: Introduction01:26

Transient Ischemic Attack l: Introduction

A transient ischemic attack (TIA) is a brief episode of neurological dysfunction caused by a temporary, focal reduction in cerebral blood flow. Although symptoms resemble those of an ischemic stroke, the interruption in perfusion is short-lived and does not cause permanent infarction. TIAs are clinically important because they often serve as early warning events for future stroke.Mechanisms of Transient Cerebral IschemiaTransient cerebral ischemia may arise through several mechanisms. One...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: Real-world outcomes of thrombectomy for distal medium vessel occlusions in the Middle East and North Africa region: a multicenter registry analysis.

Neuroradiology·2026
Same author

MENA-adapted guidelines for acute ischemic stroke management: a regional approach to global evidence.

Neurological research·2026
Same author

MTAS-MENA: adapting the Stroke Access Barrier Index (SABI) to enhance mechanical thrombectomy access in the Middle East and North Africa region.

Frontiers in neurology·2026
Same author

Use of Thick Maximum-Intensity Projection Brain Computed Tomography Angiography for Evaluation of Baseline Collateral Status Improves Interrater Agreement.

Stroke (Hoboken, N.J.)·2026
Same author

Ischemic core reversal on neuroimaging following endovascular reperfusion: A systematic review and meta-analysis.

Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism·2026
Same author

Comprehensive neurointervention training and service capacity in the Middle East & North Africa (NITA-MENA) study.

Neurological research·2026

Related Experiment Video

Updated: Jul 9, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

NXY-059 for acute ischemic stroke.

Kennedy R Lees1, Justin A Zivin, Tim Ashwood

  • 1Acute Stroke Unit and Cerebrovascular Clinic, University Department of Medicine and Therapeutics, Gardiner Institute, Western Infirmary, Glasgow, United Kingdom. k.r.lees@clinmed.gla.ac.uk

The New England Journal of Medicine
|February 10, 2006
PubMed
Summary
This summary is machine-generated.

NXY-059, a neuroprotective agent, reduced disability in acute ischemic stroke patients within 90 days. However, it did not improve neurological function, warranting further research for stroke treatment.

More Related Videos

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
09:42

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

Induction of Acute Ischemic Stroke in Mice Using the Distal Middle Artery Occlusion Technique
07:34

Induction of Acute Ischemic Stroke in Mice Using the Distal Middle Artery Occlusion Technique

Published on: December 15, 2023

Related Experiment Videos

Last Updated: Jul 9, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
09:42

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

Induction of Acute Ischemic Stroke in Mice Using the Distal Middle Artery Occlusion Technique
07:34

Induction of Acute Ischemic Stroke in Mice Using the Distal Middle Artery Occlusion Technique

Published on: December 15, 2023

Area of Science:

  • Neuroscience
  • Clinical Neurology
  • Pharmacology

Background:

  • NXY-059 is a free-radical-trapping agent demonstrating neuroprotection in animal stroke models.
  • Its efficacy in reducing human disability after acute ischemic stroke was investigated.

Purpose of the Study:

  • To evaluate the effectiveness of NXY-059 in reducing disability in patients with acute ischemic stroke.
  • To assess the impact of NXY-059 on neurological functioning and adverse events.

Main Methods:

  • A randomized, double-blind, placebo-controlled trial involving 1722 patients with acute ischemic stroke.
  • Patients received a 72-hour infusion of NXY-059 or placebo within 6 hours of stroke onset.
  • The primary outcome was disability at 90 days, measured by the modified Rankin scale.

Main Results:

  • NXY-059 significantly improved the modified Rankin scale scores compared to placebo (P=0.038).
  • No significant improvement was observed in National Institutes of Health Stroke Scale (NIHSS) scores or Barthel index.
  • In a subgroup analysis, NXY-059 reduced hemorrhagic transformation and symptomatic intracranial hemorrhage in patients also receiving alteplase.

Conclusions:

  • NXY-059 administration within six hours of acute ischemic stroke onset significantly improved disability at 90 days.
  • The drug did not significantly improve neurological functioning as measured by NIHSS.
  • Further research is required to confirm the benefits of NXY-059 in ischemic stroke treatment.